BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26521996)

  • 1. Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis?
    Ayan AK; Erdemci B; Orsal E; Bayraktutan Z; Akpinar E; Topcu A; Turkeli M; Seven B
    Rev Esp Med Nucl Imagen Mol; 2016; 35(2):102-6. PubMed ID: 26521996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
    Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The possibility of the serum concentration of osteocalcin determination in lung cancer patients with suspected bone metastases].
    Weissensteiner J; Babušíková E
    Klin Onkol; 2015; 28(1):51-6. PubMed ID: 25692755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer.
    Tomita M; Shimizu T; Ayabe T; Onitsuka T
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):244-7. PubMed ID: 22897792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients.
    Karapanagiotou EM; Terpos E; Dilana KD; Alamara C; Gkiozos I; Polyzos A; Syrigos KN
    Med Oncol; 2010 Jun; 27(2):332-8. PubMed ID: 19373566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
    Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
    BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorine-18-fluorodeoxyglucose-positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal-related events.
    Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Koizumi T; Oguchi K
    Thorac Cancer; 2019 Apr; 10(4):980-987. PubMed ID: 30883012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC.
    Dogan I; Karyagar S; Karyagar SS; Kahraman C; Alver A
    Ann Nucl Med; 2014 Nov; 28(9):829-35. PubMed ID: 24990528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
    Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
    Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.
    Carbone F; Grossi F; Bonaventura A; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Biello F; Rossi G; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
    Clin Exp Metastasis; 2019 Oct; 36(5):449-456. PubMed ID: 31376097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of 18-FDG uptake in early stage NSCLC.
    Chen JC; Huang TW; Cheng YL; Chang H; Tzao C; Huang WS; Lee SC
    Thorac Cardiovasc Surg; 2009 Oct; 57(7):413-6. PubMed ID: 19795329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
    Ding CY; Guo Z; Li YY; Li TR
    Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
    [No Abstract]   [Full Text] [Related]  

  • 15. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
    Ak I; Sivrikoz MC; Entok E; Vardareli E
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
    Hang ZQ; Zheng MF; Huang JH
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
    Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
    Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Value of
    Morita S; Suda T; Oda C; Kobayashi M; Hoshi T; Kanefuji T; Yagi K; Hasegawa G; Terai S
    Intern Med; 2019 Feb; 58(3):415-418. PubMed ID: 30146594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer.
    Ma R; Xu H; Wu J; Sharma A; Bai S; Dun B; Jing C; Cao H; Wang Z; She JX; Feng J
    Oncotarget; 2017 Mar; 8(12):18901-18913. PubMed ID: 28121629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.